The use of glucagon-like peptide-1 (GLP-1) medications for weight loss in adults aged 65 and older is gaining attention, according to a recent systematic review led by Dr. Alissa Chen from the Yale School of Medicine. While these drugs show promise for obesity management, their effectiveness and safety in older populations remain under-researched. This demographic often has unique health goals, primarily focused on enhancing functional abilities and managing chronic conditions.
Dr. Chen emphasizes that older adults frequently seek to achieve specific outcomes through weight loss, such as improved mobility and reduced joint pain. Many are also interested in the potential benefits of GLP-1 medications for comorbidities like heart disease and sleep apnea. “Their goals are usually aimed at improving outcomes—like being able to walk longer distances without knee pain or getting on the floor to play with their grandchildren,” she explains.
The review highlighted a significant gap in research concerning the impact of obesity medications on older adults. One key finding showed that this age group experienced a higher rate of gastrointestinal side effects when using anti-obesity drugs. Furthermore, the study noted that older adults were more likely to discontinue these medications compared to younger patients. “Larger and more targeted studies are needed to guide clinical care for older adults struggling with obesity,” Dr. Chen asserts.
Understanding Unique Needs of Older Adults
Dr. Kasia Lipska, an associate professor at Yale and a mentor to Dr. Chen, points out that older adults have distinct medical needs and goals that should inform obesity treatment approaches. “If we can better understand those needs and goals, we can provide older adults with obesity with the care they need,” Lipska states.
Older individuals may face adverse effects when taking GLP-1 medications, particularly due to potential interactions with other prescriptions. For instance, the risk of falls may increase due to dehydration associated with these drugs. “These medications are transforming obesity care, but we still don’t have clear evidence on how they perform in people over 65,” Lipska notes. Understanding the safety profile of GLP-1 medications in this population is critical before widespread adoption in clinical practice.
Chen and her team are actively working to gather more data on the implications of GLP-1 medications for older adults. She is spearheading two studies focused on veterans aged 65 and older. The first study, conducted at the VA Connecticut Healthcare System, aims to assess how GLP-1 agonists help individuals meet their health goals. Participants will be interviewed prior to starting the medication to evaluate their quality of life, encompassing physical function, mood, pain levels, and expectations. Follow-up surveys will be conducted six months after treatment initiation to gauge their experiences.
The second study will analyze national VA data to examine the weight loss effects of GLP-1 agonists among older adults. This research is particularly valuable as it seeks to bridge the gap between controlled clinical trials and real-world outcomes. “How much weight do we expect them to lose? Can it help them improve their function, or does it hinder their function? What are the unforeseen adverse effects that occur when older adults take these meds?” Chen asks.
By addressing these pressing questions, Chen hopes to illuminate important considerations for older adults using GLP-1 medications and contribute to the evolving landscape of obesity treatment. As research continues to unfold, it is clear that the unique characteristics of older adults demand a tailored approach in the realm of obesity management, paving the way for more effective and safer interventions.
